Semaglutide programs start at $250 per month , and Tirzepatide programs start at $350 per month
This hegemony is about to be permanently disrupted by a new mass market, chronic disease area, which unusually is seeing very high levels of out of pocket spend- in February 2024, Novo Nordisks CEO noted that in Europe, 80% of Wegovy sales so far were paid for out of pocket by patients- showing, against preconception, that European patients were as willing as Americans to pay for their own obesity medications 5
They slow gastric emptying, reduce hunger, and increase feelings of fullness, which helps reduce calorie intake and promote weight loss
Williams WP 3rd, McLin DE 3rd, Dressman MA, Neubauer DN
10 (Suppl 2): 291S298S
Cost and Affordability This is where many patients start weighing the pros and cons